Difference between revisions of "Ribociclib (Kisqali)"
Jump to navigation
Jump to search
m (Text replacement - "[[File:" to "[[:File:") |
m |
||
| Line 13: | Line 13: | ||
*3/13/2017: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm546438.htm Initial FDA approval] in combination with an [[:Category:Aromatase inhibitors|aromatase inhibitor]] as initial endocrine-based therapy for the treatment of postmenopausal women with [[Biomarkers#HR|hormone receptor (HR)]]-[[Biomarkers#Expression|positive]], [[Biomarkers#HER2|human epidermal growth factor receptor 2 (HER2)]]-[[Biomarkers#Normal_expression|negative]] advanced or metastatic [[breast cancer]]. ''(Based on MONALEESA-2 and MONALEESA-3)'' | *3/13/2017: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm546438.htm Initial FDA approval] in combination with an [[:Category:Aromatase inhibitors|aromatase inhibitor]] as initial endocrine-based therapy for the treatment of postmenopausal women with [[Biomarkers#HR|hormone receptor (HR)]]-[[Biomarkers#Expression|positive]], [[Biomarkers#HER2|human epidermal growth factor receptor 2 (HER2)]]-[[Biomarkers#Normal_expression|negative]] advanced or metastatic [[breast cancer]]. ''(Based on MONALEESA-2 and MONALEESA-3)'' | ||
*7/18/2018: FDA approval expanded in combination with an [[:Category:Aromatase inhibitors|aromatase inhibitor]] for pre/perimenopausal women with [[Biomarkers#HR|HR]]-[[Biomarkers#Expression|positive]], [[Biomarkers#HER2|HER2]]-[[Biomarkers#Normal_expression|negative]] advanced or metastatic [[breast cancer]], as initial endocrine-based therapy. ''(No longer limited to postmenopausal women; based on MONALEESA-7)'' | *7/18/2018: FDA approval expanded in combination with an [[:Category:Aromatase inhibitors|aromatase inhibitor]] for pre/perimenopausal women with [[Biomarkers#HR|HR]]-[[Biomarkers#Expression|positive]], [[Biomarkers#HER2|HER2]]-[[Biomarkers#Normal_expression|negative]] advanced or metastatic [[breast cancer]], as initial endocrine-based therapy. ''(No longer limited to postmenopausal women; based on MONALEESA-7)'' | ||
| − | + | ==History of changes in FDA indication== | |
| + | *8/22/2017: Initial authorization | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' LEE011, LEE-011 | *'''Code names:''' LEE011, LEE-011 | ||
| Line 30: | Line 31: | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
[[Category:FDA approved in 2017]] | [[Category:FDA approved in 2017]] | ||
| + | [[Category:EMA approved in 2018]] | ||
Revision as of 14:47, 1 January 2023
General information
Class/mechanism: Cyclin-dependent kinase (CDK) 4 and 6 inhibitor. Ribociclib inhibits DNA synthesis and cancer cell growth by blocking activity of the cyclin D-CDK4/6 complex which regulates cell cycle progression and cellular proliferation by phosphorylating the retinoblastoma protein (pRb). Inhibiting pRb phosphorylation has been observed to lead to cell cycle arrest in the G1 phase.[1][2][3]
Route: PO
Extravasation: n/a
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 3/13/2017: Initial FDA approval in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. (Based on MONALEESA-2 and MONALEESA-3)
- 7/18/2018: FDA approval expanded in combination with an aromatase inhibitor for pre/perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. (No longer limited to postmenopausal women; based on MONALEESA-7)
History of changes in FDA indication
- 8/22/2017: Initial authorization
Also known as
- Code names: LEE011, LEE-011
- Brand names: Kisqali, Kryxana